ArticleMovement disorders : official journal of the Movement Disorder Society2025
Plasma Markers of Astrocytic and Axonal Integrity in Idiopathic/Isolated REM Sleep Behavior Disorder (iRBD) as Predictors of Dementia with Lewy Bodies.
Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discordance Between Striatal Dopaminergic Imaging and Motor Performances in REM Sleep Behavior Disorder.Neurology open access · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPlasma biomarkers of neurodegeneration, astrogliosis, and neuroinflammation have been studied as potential biomarkers in neurodegenerative diseases. This study investigated whether these markers may predict phenoconversion to Parkinson's disease or dementia with Lewy bodies (DLB) in idiopathic/isolated REM sleep behavior disorder (iRBD).
methodsIn this longitudinal, single-center, iRBD cohort study (enrolled 2004-2022), plasma glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), neurofilament light chain (NfL), snare-associated protein 25 (SNAP25), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and chitinase 3-like protein (YKL-40) were measured using NeuroToolKit (Roche Diagnostics International Ltd). Associations between baseline plasma biomarkers and eventual development of manifest synucleinopathy during follow-up (up to 11 years) were assessed.
resultsA total of 143 iRBD participants (110 male, 67.7 ± 8.0 years) were included. Compared with non-phenoconverters, DLB-converters had higher baseline GFAP (0.115 vs. 0.071 ng/ml, P = 0.002) and NfL (3.55 vs. 2.51 pg/ml, P = 0.010). Baseline levels predicted DLB using non-phenoconverters without mild cognitive impairment as reference with area under the curve (AUC) = 0.79 for GFAP and 0.84 for NfL.
conclusionHigher plasma GFAP and NfL were associated with increased risk of developing DLB in prodromal synucleinopathies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.